Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGO-Cs01p in CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
NCT06849401Phase 1Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of VGO-Cs01p in T-cell acute lymphoblastic leukemia (T-ALL), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Incidence and severity of adverse events at 1 year. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
VGO-Cs01p
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT06849401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849401.